Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The triple receptor agonist retatrutide gave rise to substantial reductions in body weight in adults with obesity, according to a recent phase 2, randomised placebo-controlled trial
The price is $199 plus the prescription cost
The comparison with ranitidine, a standard acid-reducing medication, proved particularly instructive
CagriSema has the stronger evidence base with completed phase 3 REDEFINE trials showing 20.4% weight loss, and is closer to potential approval
[Crossref] 19
"CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes"
US$ 24.02
US$ 21.55
US$ 29.05
US$ 22.69
US$ 25.65
US$ 22.12
US$ 29.91
